Abstracts tagged "Work Disability"

Abstract Number: 549 • 2016 ACR/ARHP Annual Meeting
Work Status in Patients with Rheumatoid Arthritis Who Have Poor Prognostic Factors: Findings from a US Observational Cohort
E Alemao¹, LR Harrold², HJ Litman³, SE Connolly⁴, S Kelly¹, W Hua³, L Rosenblatt¹, S Rebello⁵ and JM Kremer⁶, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Massachusetts Medical School, Worcester, MA, ³Corrona, Southborough, MA, ⁴Department of Immunology and Inflammation, Bristol-Myers Squibb, Princeton, NJ, ⁵Epidemiology, Corrona, Southborough, MA, ⁶The Albany Medical College, Albany, NY
Background/Purpose: A number of studies have demonstrated the association between disease activity and work productivity in patients (pts) with RA. However, the relationship between work…
Abstract Number: 702 • 2016 ACR/ARHP Annual Meeting
Treatment with Golimumab or Infliximab Reduces Health Resource Utilization and Increases Work Productivity in Patients with Ankylosing Spondylitis in a Large, Prospective Real-Life Cohort
Pascal Claudepierre¹, Filip van Den Bosch², Piercarlo Sarzi-Puttini³, Shiva Sajjan⁴, N Vastesaeger⁵, Marinella Govoni⁶ and Sumesh Kachroo⁷, ¹Hôpital Henri Mondor, Créteil, France, ²Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ⁴Merck & Co., Inc., Kenilworth, NJ, ⁵Merck Sharp & Dohme, Belgium, Brussels, Belgium, ⁶Via Tasso 14, Merck Sharp & Dohme, Italy, Cento, Italy, ⁷CORE, Merck & Co., Inc., Kenilworth, NJ
Background/Purpose: We evaluated the effect of the anti-tumor necrosis factor (TNF) agents, golimumab (GLM) and infliximab (IFX), on healthcare resource utilization (HCRU) and work productivity…
Abstract Number: 2479 • 2016 ACR/ARHP Annual Meeting
Work Productivity in Early Rheumatoid Arthritis Patients Treated before and after Implementation of a Treat-to-Target Strategy
Siri Lillegraven¹, Maria Dahl Mjaavatten¹, Nina P. Sundlisater¹, Anna-Birgitte Aga¹, Inge C Olsen², Till Uhlig¹, Daniel H. Solomon³, Tore K Kvien¹, Espen A. Haavardsholm¹ and the ARCTIC Study Group, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a known cause of work productivity loss. Participation in work-related activities is defined as part of the primary goal of…
Abstract Number: 2670 • 2016 ACR/ARHP Annual Meeting
Work Disability in Newly Diagnosed Patients with Primary SjöGren’s Syndrome – a Population-Based Cohort Study
Thomas Mandl¹, Tanja Schjødt Jørgensen², Marie Skougaard Nielsen², Peter Olsson¹ and Lars Erik Kristensen³, ¹Dept of Rheumatology, Skane University Hospital Malmö, Lund University, Malmo, Sweden, ²The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ³The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark
Background/Purpose: To study long-term work disability (WD) and possible predictors in newly diagnosed patients with primary Sjögren’s syndrome (pSS). Methods: 51 pSS patients…
Abstract Number: 2730 • 2016 ACR/ARHP Annual Meeting
Impact of Disease Flare Perception on Work Productivity and Treatment Satisfaction in Patients with Psoriatic Arthritis in Real World Setting
William Tillett^1,2, James Piercy³, Su Chen⁴ and Fabiana Ganz⁵, ¹Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ²Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Adelphi Real World, Cheshire, United Kingdom, ⁴AbbVie, North Chicago, IL, ⁵Neuhofstrasse 23, AbbVie, Baar, Switzerland
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) may experience temporary worsening of symptoms or disease flare, which can be painful enough to interfere with day-to-day…
Abstract Number: 653 • 2015 ACR/ARHP Annual Meeting
Clinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Désirée van der Heijde¹, Juergen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Klinikum Bielefeld, Bielefeld, Germany, ⁴UCB Pharma, Brussels, Belgium, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Axial spondyloarthritis (axSpA) includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA).1 AS significantly affects patient (pt) workplace productivity in both performance and disease-related absenteeism.2…
Abstract Number: 2481 • 2015 ACR/ARHP Annual Meeting
Work Disability in a Cohort of Patients with Psoriatic Arthritis
Cecilia Zaffarana¹, Osvaldo Luis Cerda¹, Josefina Gallino Yanzi¹, Margarita Landi¹, Emilce Schneeberger¹, Ignacio Carrillo¹, María del Carmen Gonzalez Guzmán¹, Jose A Maldonado Cocco¹, Susana Gagliardi¹ and Gustavo Citera², ¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Consultorios Reumatológicos Pampa, Buenos Aires, Argentina
Background/Purpose: Several studies showed that unemployment and work disability are high in patients with Psoriatic Arthritis (PsA). Te purpose of this study is to evaluate work…
Abstract Number: 2648 • 2015 ACR/ARHP Annual Meeting
Vitality, Presenteeism, and Their Determinants in Patients with Early Rheumatoid Arthritis Treated with a 6-Month Induction Infliximab Therapy Added on a Triple Combination Therapy
Vappu Rantalaiho¹, Marjatta Leirisalo-Repo², Hannu Kautiainen³, Petri Mankinen⁴, Janne Martikainen⁵ and Kari Puolakka⁶, ¹Department of Internal Medicine, Center for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland, ²Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ³Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁴Pharmacoeconomics & Outcomes Research Unit (PHORU), School of Pharmacy, University of Eastern Finland, Kuopio, Finland, ⁵Pharmacoeconomics and Outcomes Research Unit, School of Pharmacy, University of Eastern Finland, Kuopio, Finland, ⁶Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland
Background/Purpose: To evaluate vitality, reduced paid and unpaid work ability, and productivity losses for patients with early rheumatoid arthritis (RA) available for work force at…
Abstract Number: 2860 • 2015 ACR/ARHP Annual Meeting
Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Arthur Kavanaugh¹, Dafna Gladman², Désirée van der Heijde³, Oana Purcaru⁴ and Philip J. Mease⁵, ¹University of California San Diego, La Jolla, CA, ²University of Toronto, Toronto, ON, Canada, ³Leiden University Medical Center, Leiden, Netherlands, ⁴UCB Pharma, Brussels, Belgium, ⁵Rheumatology Research, Swedish Medical Center, Seattle, WA
Background/Purpose: Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 Few studies have…
Abstract Number: 2034 • 2014 ACR/ARHP Annual Meeting
A Treat-to-Target Strategy Preserves Work Capacity in Early Rheumatoid Arthritis (RA)
Mihir D. Wechalekar¹, Steve Quinn², Susan Lester³, Ella Shanahan⁴, Robert Metcalf⁵, E. Michael Shanahan⁶ and Susanna Proudman^4,7, ¹Flinders University School of Medicine, Adelaide, Australia, ²Flinders Clinical Effectiveness, Flinders University, Adelaide, Australia, ³Rheumatology Unit, Queen Elizabeth Hospital, Woodville South, Australia, ⁴University of Adelaide, Discipline of Medicine, Adelaide, Australia, ⁵University of Adelaide, Adelaide, Australia, ⁶Rheumatology, Flinders University, Bedford Park, South Australia, Australia, ⁷Department of Rheumatology, Royal Adelaide Hospital, SA, Australia
Background/Purpose Historical data (1)indicate a third of patients with RA are unable to work within the first 5 years of diagnosis. Our aim was to…
Abstract Number: 1552 • 2014 ACR/ARHP Annual Meeting
Sustained Improvements in Workplace and Household Productivity and Social Participation with Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis
Arthur Kavanaugh¹, Dafna D. Gladman², Désirée van der Heijde³, Oana Purcaru⁴ and Philip J. Mease⁵, ¹University of California San Diego, La Jolla, CA, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴UCB Pharma, Brussels, Belgium, ⁵Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 The previous results…
Abstract Number: 577 • 2014 ACR/ARHP Annual Meeting
A Substantial Decrease in Work Productivity and Physical Health-Related Quality of Life in Chronic Back Pain of Recent Onset: Data from the SPACE-Cohort
A Roeterink¹, M de Hooge², R. van den Berg², H Dagfinrud³, M Turina⁴, M. van Oosterhout⁵, D. van der Heijde¹ and F van Gaalen², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Oslo City Dept of Rheumat, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Groene Hartziekenhuis, Gouda, Netherlands
Background/Purpose: Ankylosing spondylitis is associated with work productivity (WP) loss and a decreased health-related quality of life (HRQoL). Little is known about WP loss and…
Abstract Number: 575 • 2014 ACR/ARHP Annual Meeting
Disease Activity Strongly Influences Work Productivity and Physical Health Related Quality of Life in Early Axial Spondyloarthritis: Data from the SPACE-Cohort
A Roeterink¹, M de Hooge², R. van den Berg², H Dagfinrud³, R Landewé⁴, M. van Oosterhout⁵, R Ramonda⁶, D. van der Heijde¹ and F van Gaalen², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Oslo City Dept of Rheumat, Diakonhjemmet Hospital, Oslo, Norway, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Groene Hartziekenhuis, Gouda, Netherlands, ⁶Rheumatology Unit, University of Padova, Padova, Italy
Background/Purpose: In early onset axial spondyloarthritis (axSpA), not much is known about the relationship between disease activity and work productivity loss (WPL) or disease activity…
Abstract Number: 105 • 2014 ACR/ARHP Annual Meeting
Resource Use and Health Related Quality of Life Burden of Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey
Robert Morlock¹, Natalia M. Flores², Kathy Annunziata³, J. Chapnick⁴ and Sulabha Ramachandran⁵, ¹4939 Directors Place, Ardea Biosciences, San Diego, CA, ²Kantar Health, Foster City, CA, ³Kantar Health, Princeton, NJ, ⁴Kantar Health, Horsham, PA, ⁵AstraZeneca, Wilmington, DE
Background/Purpose: Gout is caused by chronic high serum uric acid (SUA) levels (i.e., hyperuricemia), which leads to the deposition of monosodium urate crystals in musculoskeletal…
Abstract Number: 2560 • 2014 ACR/ARHP Annual Meeting
Sustained Improvements in Workplace and Household Productivity and Social Participation with Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Desiree van der Heijde¹, Juergen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Endokrinologikum, Berlin, Germany, ⁴Allee De La Recherche 60, UCB Pharma, Anderlecht, Belgium, ⁵University of California San Diego, La Jolla, CA
Background/Purpose Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS, meeting modified New York criteria) and axSpA with no sacroiliitis on X-ray (non-radiographic axSpA, nr-axSpA). Previous…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].